Literature DB >> 25926585

Emergency reversal of dabigatran for emergency surgery.

Thomas Puttick1, Rahul Bahl1, Hussein Mohamedbhai1.   

Abstract

An 80-year-old woman had the anticoagulant effect of dabigatran etexilate reversed using factor eight inhibitor bypassing activity (FEIBA) in order to facilitate emergency surgery for an incarcerated femoral hernia. She had atrial fibrillation was taking the anticoagulant for stroke prevention. That afternoon her international normalised ratio (INR) was 1.3 and activated partial thromboplastin time ratio (APPTr) was 2.17, having taken dabigatran that morning. 3000 units of FEIBA and 10 mg of vitamin K were administered and she was taken to theatre for emergency surgery. Surgery was successful, total blood loss was less than 100 mL and there were no complications. The following morning she had an INR of 1.1 and APPTr of 1.49. She made an uneventful postoperative recovery and was discharged home. There is a limited evidence base guiding practice in the clinical scenario described. The only controlled studies available are animal experiments. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25926585      PMCID: PMC4422923          DOI: 10.1136/bcr-2014-209057

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.

Authors:  Trevor Baglin; David Keeling; Steve Kitchen
Journal:  Br J Haematol       Date:  2012-09-13       Impact factor: 6.998

Review 2.  Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

Authors:  Scott Kaatz; Peter A Kouides; David A Garcia; Alex C Spyropolous; Mark Crowther; Jim D Douketis; Anthony K C Chan; Andra James; Stephan Moll; Thomas L Ortel; Elizabeth M Van Cott; Jack Ansell
Journal:  Am J Hematol       Date:  2012-04-04       Impact factor: 10.047

3.  The management of atrial fibrillation: summary of updated NICE guidance.

Authors:  Clare Jones; Vicki Pollit; David Fitzmaurice; Campbell Cowan
Journal:  BMJ       Date:  2014-06-19

4.  Dabigatran: how the drug company withheld important analyses.

Authors:  Deborah Cohen
Journal:  BMJ       Date:  2014-07-23

5.  Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding.

Authors:  Henna Wong; David Keeling
Journal:  Br J Haematol       Date:  2014-03-12       Impact factor: 6.998

6.  Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.

Authors:  Robert G Hart; Hans-Christoph Diener; Sean Yang; Stuart J Connolly; Lars Wallentin; Paul A Reilly; Michael D Ezekowitz; Salim Yusuf
Journal:  Stroke       Date:  2012-04-05       Impact factor: 7.914

7.  Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity.

Authors:  William E Dager; Robert C Gosselin; A Josh Roberts
Journal:  Crit Care Med       Date:  2013-05       Impact factor: 7.598

8.  A specific antidote for dabigatran: functional and structural characterization.

Authors:  Felix Schiele; Joanne van Ryn; Keith Canada; Corey Newsome; Eliud Sepulveda; John Park; Herbert Nar; Tobias Litzenburger
Journal:  Blood       Date:  2013-03-08       Impact factor: 22.113

9.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

Review 10.  The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.

Authors:  Raza Alikhan; Rachel Rayment; David Keeling; Trevor Baglin; Gary Benson; Laura Green; Scott Marshall; Raj Patel; Sue Pavord; Peter Rose; Campbell Tait
Journal:  Emerg Med J       Date:  2013-02-22       Impact factor: 2.740

View more
  3 in total

Review 1.  The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review.

Authors:  Maureane Hoffman; Joshua N Goldstein; Jerrold H Levy
Journal:  Int J Emerg Med       Date:  2018-12-03

Review 2.  Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.

Authors:  Jennifer A Frontera; John J Lewin; Alejandro A Rabinstein; Imo P Aisiku; Anne W Alexandrov; Aaron M Cook; Gregory J del Zoppo; Monisha A Kumar; Ellinor I B Peerschke; Michael F Stiefel; Jeanne S Teitelbaum; Katja E Wartenberg; Cindy L Zerfoss
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

3.  The Role of FEIBA in Reversing Novel Oral Anticoagulants in Intracerebral Hemorrhage.

Authors:  Jamil R Dibu; Jonathan M Weimer; Christine Ahrens; Edward Manno; Jennifer A Frontera
Journal:  Neurocrit Care       Date:  2016-06       Impact factor: 3.210

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.